CliffBio
small molecule

TABRECTA

CAPMATINIB HYDROCHLORIDE

Loss of exclusivityJuly 2035latest FDA-listed patent expiry
CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand nameTABRECTA
Active ingredientCAPMATINIB HYDROCHLORIDE
StrengthEQ 150MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2020
Marketing statusRX

Listed patents

PatentExpiresType
10596178July 2035product
12208101July 2035product
7767675November 2032substance, product
8420645June 2031substance, product
8901123May 2029use U-2813
12084449November 2027use U-2813
8461330November 2027substance, product

Regulatory exclusivity

CodeExpires
ODE-291May 2027

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TABRECTA patent cliff — loss of exclusivity July 2035 | CliffBio